Regulated Information

To guarantee transparency and sustainability, we abide by a strict set of rules and regulations.

Use the links below to review investor information. If more information is needed, please contact us.

2024

No regulated information available

September 05, 2024

2024 Half-Year Financial Report

Download

September 05, 2024

Notice of publication of the 2024 Half-Year Financial Report

Download

March 28, 2024

Release of the Universal Registration Document including the Annual Financial Report as of December 31, 2023

Download

December 05, 2024

November 2024 - Declaration about number of shares issued and number of voting rights

Download

November 06, 2024

October 2024 - Declaration about number of shares issued and number of voting rights

Download

October 08, 2024

September 2024 - Declaration about number of shares issued and number of voting rights

Download

September 10, 2024

August 2024 - Declaration about number of shares issued and number of voting rights

Download

August 06, 2024

July 2024 - Declaration about number of shares issued and number of voting rights

Download

July 05, 2024

June 2024 - Declaration about number of shares issued and number of voting rights

Download

June 05, 2024

May 2024 - Declaration about number of shares issued and number of voting rights

Download

May 06, 2024

April 2024 - Declaration about number of shares issued and number of voting rights

Download

April 05, 2024

March 2024 - Declaration about number of shares issued and number of voting rights

Download

March 04, 2024

February 2024 - Declaration about number of shares issued and number of voting rights

Download

February 02, 2024

January 2024 - Declaration about number of shares issued and number of voting rights

Download

November 11, 2024

Canada's First Center of Excellence in the Fight Against Antimicrobial Resistance

Download

October 29, 2024

Third-Quarter 2024 Business Review

Download

October 14, 2024

VIDAS Vitamin B12 TOTAL CE-Marking - Press Release

Download

September 19, 2024

Innovation Center Philadelphia Opening - Press Release

Download

September 04, 2024

First-Half 2024 Results - bioMérieux Press Release

Download

June 25, 2024

BIOFIRE® SPOTFIRE® R/ST Panel Mini FDA Clearance - Press Release

Download

June 21, 2024

VITEK REVEAL FDA Clearance - Press Release

Download

May 24, 2024

VIDAS TBI FDA Clearance - Press Release

Download

May 23, 2024

Malawi MoH, bioMérieux and Pfizer AMR Collaboration - Press Release

Download

April 09, 2024

bioMérieux presents its new 5-year strategic plan

Download

April 09, 2024

First-Quarter 2024 Business Review - Press Release

Download

April 03, 2024

Trusted Third Party Model by bioMérieux and Mérieux NutriSciences - Press Release

Download

March 28, 2024

FDA clearance and CLIA-waiver for the BIOFIRE® SPOTFIRE® R/ST Panel

Download

March 14, 2024

bioMérieux – 2023 Financial Results - Press Release

Download

January 12, 2024

Nominations Executive Committee - Press Release

Download

January 08, 2024

bioMérieux acquires LUMED - Press Release

Download

March 25, 2024

AG 2024 - Notice preparatory documents - General shareholders meeting.pdf

Download

No regulated information available

May 23, 2024

AG 2024 - Description of the shares repurchase program

Download

No regulated information available

2023

September 04, 2023

2023 HY Financial Report

Download

September 04, 2023

Notice of publication of the 2023 HY Financial Report

Download

March 22, 2023

Release of the Universal Registration Document including the Annual Financial Report as of December 31, 2022

Download

No regulated information available

January 05, 2024

December 2023 - Declaration about number of shares issued and number of voting rights

Download

December 07, 2023

November 2023 - Declaration about number of shares issued and number of voting rights

Download

November 09, 2023

October 2023 - Declaration about number of shares issued and number of voting rights

Download

October 05, 2023

September 2023 - Declaration about number of shares issued and number of voting rights

Download

September 05, 2023

August 2023 - Declaration about number of shares issued and number of voting rights

Download

August 04, 2023

July 2023 - Declaration about number of voting rights and shares

Download

July 04, 2023

June 2023 - Declaration about number of shares issued and number of voting rights

Download

June 05, 2023

May 2023 - Declaration about number of shares issued and number of voting rights

Download

May 04, 2023

April 2023 - Declaration about number of shares issued and number of voting rights

Download

April 05, 2023

March 2023 - Declaration about number of shares issued and number of voting rights

Download

March 07, 2023

February 2023 - Declaration about number of shares issued and number of voting rights

Download

February 03, 2023

January 2023 - Declaration about number of shares issued and number of voting rights

Download

No regulated information available

November 28, 2023

Launch of a new industrial chair, in Lyon on viral respiratory infections - Press Release

Download

October 25, 2023

Third-Quarter 2023 Business Review - Press Release

Download

October 19, 2023

bioMérieux Strategic Investment In Oxford Nanopore - Press Release

Download

October 03, 2023

CE-marking of VIDAS TBI (GFAP, UCH-L1) - Press Release

Download

September 21, 2023

bioMérieux submits Dual 510(k) and CLIA-waiver application to FDA for the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel - Press Release

Download

August 31, 2023

First-Half 2023 Results - Press Release

Download

June 27, 2023

Jennifer Zinn appointed Executive Vice President Clinical Operations - Press Release

Download

June 13, 2023

bioMérieux_PR_Governance_20230614.pdf

Download

May 09, 2023

bioMérieux receives US FDA CLIA-waiver for the BIOFIRE® SPOTFIRE® Respiratory (R) Panel Mini

Download

April 26, 2023

First-Quarter 2023 Business Review - Press Release

Download

April 14, 2023

Oxford Nanopore and bioMérieux to enter into a strategic partnership agreement - Press Release

Download

April 13, 2023

BIOFIRE SPOTFIRE R Panel Mini FDA-cleared - Press Release

Download

April 06, 2023

VITEK REVEAL FDA Submission - Press Release

Download

April 03, 2023

BIOFIRE FIREWORKS launch - Press Release

Download

March 09, 2023

BioFire Defense partners with BARDA - Press Release

Download

March 07, 2023

bioMérieux - 2022 Financial Results - Press Release

Download

February 09, 2023

BIOFIRE SPOTFIRE FDA CLEARANCE

Download

January 24, 2023

Maestria Launch - Press Release

Download

No regulated information available

January 04, 2024

Biannual report on bioMérieux's liquidity agreement as of December 30, 2023

Download

November 20, 2023

Biannual report on bioMérieux's liquidity agreement as of June 30, 2023

Download

September 21, 2023

Disclosure of trading in own shares on september 18th

Download

September 21, 2023

Disclosure of trading in own shares on june 23d

Download

May 23, 2023

AG 2023 - Description of shares repurchase program

Download

No regulated information available

2022

September 01, 2022

Notice of publication of the 2022 HY Financial Report

Download

August 31, 2022

2022 HY Financial Report

Download

March 21, 2022

Release of 2021 URD

Download

No regulated information available

January 04, 2023

December 2022 - Declaration about number of shares issued and number of voting rights

Download

December 05, 2022

November 2022 - Declaration about number of shares issued and number of voting rights

Download

November 07, 2022

October 2022 - Declaration about number of shares issued and number of voting rights

Download

October 04, 2022

September 2022 - Declaration about number of shares issued and number of voting rights

Download

September 02, 2022

August 2022 - Declaration about number of shares issued and number of voting rights

Download

August 02, 2022

July 2022 – Declaration about number of shares issued and number of voting rights

Download

July 04, 2022

June 2022 - Declaration about number of shares issued and number of voting rights

Download

June 03, 2022

May 2022 - Declaration about number of shares issued and number of voting rights

Download

May 03, 2022

April 2022 - Declaration about number of shares issued and number of voting rights

Download

April 04, 2022

March 2022 – Declaration about number of shares issued and number of voting rights

Download

March 07, 2022

February 2022 - Declaration about number of shares issued and number of voting rights

Download

February 03, 2022

January 2022 - Declaration about number of shares issued and number of voting rights

Download

January 10, 2022

December 2021 - Declaration about number of shares issued and number of voting rights

Download

No regulated information available

December 19, 2022

VIDAS KUBE CE-Marking - Press Release

Download

December 14, 2022

bioMérieux - Increased outlook for full-year 2022 and 2023 guidance preview

Download

October 26, 2022

Third-Quarter 2022 Business Review - Press Release

Download

September 23, 2022

Sepsis Bundles Survey - Press Release - UK

Download

September 20, 2022

Sepsis Bundles Survey - Press Release

Download

August 30, 2022

First-Half 2022 Results

Download

August 22, 2022

The SPECIFIC REVEAL® Rapid AST System has received Breakthrough Device Designation from the FDA

Download

July 26, 2022

20220728 _PR_VIDAS_NEPHROCHECK_FDA_Clearance_EN.pdf

Download

July 01, 2022

Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance

Download

June 30, 2022

bioMérieux launches 3P® ENTERPRISE

Download

May 19, 2022

Closing of the acquisition of Specific Diagnostics

Download

May 11, 2022

bioMérieux announces the CE marking of VIDAS® tests for Chikungunya virus diagnosis

Download

May 02, 2022

bioMérieux receives De Novo FDA Authorization for its BIOFIRE® Joint Infection (JI) Panel

Download

April 12, 2022

bioMérieux strengthens its commitment to fight antimicrobial resistance with the acquisition of Specific Diagnostics, an innovative company focusing on fast AST solution

Download

April 11, 2022

bioMérieux – First-Quarter 2022 Business Review

Download

March 17, 2022

bioMérieux receives FDA 510(k) clearance for its VITEK® MS PRIME new MALDI-TOF mass spectrometry identification system

Download

March 01, 2022

bioMérieux – 2021 Financial Results

Download

February 14, 2022

MYACUTECASE™, a free mobile application by bioMérieux to support clinicians in decision-making and monitoring of patients using emergency and critical care diagnostics

Download

January 03, 2022

French multidisciplinary consortium ARPEGE awarded public funding of close to €9 million to fight antibiotic resistance

Download

April 12, 2022

AG 2022 - Notice of information relating to preparatory documents for the Ordinary and Extraordinary Shareholders' Meeting of May 23, 2022

Download

No regulated information available

2011

October 20, 2011

bioMérieux - Business Review for the nine months ended September 30, 2011

Download

September 06, 2011

Rapport financier semestriel relatif au premier semestre clos le 30 juin 2011

Download

July 19, 2011

bioMérieux - First-Half 2011 Business Review

Download

June 30, 2011

Registration Document and Annual Financial Report 2010

Download

April 21, 2011

bioMérieux - First-Quarter 2011 Business Review

Download

January 19, 2011

bioMérieux – 2010 Business Review

Download

No regulated information available

December 05, 2011

November 2011 - Declaration about number of shares issued and number of voting rights

Download

November 04, 2011

October 2011 - Declaration about number of shares issued and number of voting rights

Download

October 04, 2011

September 2011 - Declaration about number of shares issued and number of voting rights

Download

September 02, 2011

August 2011 - Declaration about number of shares issued and number of voting rights

Download

August 29, 2011

July 2011 - Declaration about number of shares issued and number of voting rights

Download

July 04, 2011

June 2011 - Declaration about number of shares issued and number of voting rights

Download

June 10, 2011

May 2011 - Declaration about number of shares issued and number of voting rights

Download

May 03, 2011

April 2011 - Declaration about number of shares issued and number of voting rights

Download

April 04, 2011

March 2011 - Declaration about number of shares issued and number of voting rights

Download

March 02, 2011

February 2011 - Declaration about number of shares issued and number of voting rights

Download

January 31, 2011

January 2011 - Declaration about number of shares issued and number of voting rights

Download

January 04, 2011

December 2010 - Declaration about number of shares issued and number of voting rights

Download

No regulated information available

December 07, 2011

bioMérieux - Information on 2011 sales objective

Download

November 17, 2011

bioMérieux Initiative to Support European Antibiotic Awareness Day

Download

October 20, 2011

bioMérieux Business Review for the nine months ended September 30, 2011

Download

September 27, 2011

Mise en œuvre du retrait obligatoire visant les actions AES Chemunex

Download

September 06, 2011

bioMérieux - First-Half Results at June 30, 2011

Download

July 27, 2011

New Study Reports: CancerTYPE ID Expands Tumor Type Coverage and Demonstrates Clinical Utility - CancerTYPE ID is Now a Covered Benefit for Medicare Part B Patients

Download

July 27, 2011

New Study Reports: CancerTYPE ID Expands Tumor Type Coverage and Demonstrates Clinical Utility - CancerTYPE ID is Now a Covered Benefit for Medicare Part B Patients

Download

July 19, 2011

bioMérieux - First-Half 2011 Business Review

Download

July 19, 2011

bioMérieux Expands its Infectious Disease Offering with Acquisition of ARGENE, Specialized in Molecular Diagnostics for Immunocompromised Patients

Download

June 30, 2011

World HAI Forum: Global Call to Action to Fight Antibiotic Resistance

Download

June 22, 2011

bioMérieux Launches Groundbreaking Salmonella Detection Technology to Improve Food Safety

Download

May 24, 2011

bioMérieux Receives FDA Clearance for NucliSENS EasyQ® MRSA, Automated, Rapid Molecular Screening Test

Download

May 19, 2011

bioMérieux Becomes the World Leader in Food Testing with AES Laboratoire Acquisition

Download

May 04, 2011

bioMérieux and Labor Berlin (Charité Vivantes GmbH) to Establish Center of Excellence in Laboratory Diagnostics

Download

April 21, 2011

bioMérieux - First-Quarter 2011 Business Review

Download

April 06, 2011

bioMérieux Achieves 100th PREVI™ Isola Milestone, Installing its Automated Plate Streaker at Grady Health System

Download

March 08, 2011

bioMérieux - 2010 Financial Results

Download

January 27, 2011

Ipsen and bioMérieux enter into a broad partnership in personalized medicine

Download

January 27, 2011

Philips and bioMérieux announce milestone in the development of innovative handheld diagnostic solutions for rapid point-of-care testing

Download

January 04, 2011

bioMérieux Expands Customer Services Offer, Appointing James P. Whelan as Executive Vice President, Commercial Services

Download

No regulated information available

2021

September 02, 2021

Notice of Publication of the 2021 HY Financial Report

Download

September 01, 2021

2021 HY Financial Report

Download

August 31, 2021

bioMérieux - 2021 HY Financial Results

Download

No regulated information available

December 08, 2021

November 2021 - Declaration about number of shares issued and number of voting rights

Download

November 05, 2021

October 2021 - Declaration about number of shares issued and number of voting rights

Download

October 08, 2021

January 2021 - Declaration about number of shares issued and number of voting rights

Download

September 06, 2021

September 2021 - Declaration about number of shares issued and number of voting rights

Download

August 12, 2021

August 2021 - Declaration about number of shares issued and number of voting rights

Download

July 07, 2021

July 2021 - Declaration about number of shares issued and number of voting rights

Download

June 10, 2021

June 2021 - Declaration about number of shares issued and number of voting rights

Download

May 05, 2021

May 2021 - Declaration about number of shares issued and number of voting rights

Download

April 07, 2021

April 2021 - Declaration about number of shares issued and number of voting rights

Download

March 04, 2021

March 2021 - Declaration about number of shares issued and number of voting rights

Download

February 05, 2021

December 2020 - Declaration about number of shares issued and number of voting rights

Download

January 08, 2021

February 2021 - Declaration about number of shares issued and number of voting rights

Download

No regulated information available

December 10, 2021

bioMérieux – Increased outlook for full-year 2021

Download

December 09, 2021

Corporate Social Responsibility: bioMérieux recently received a series of official recognitions from independent third parties

Download

December 01, 2021

bioMérieux molecular tests efficiently detect SARS-CoV-2 Omicron variant

Download

October 20, 2021

Baxter and bioMérieux announce CE mark for NEPHROCLEAR™ CCL14 test to predict persistent severe acute kidney injury

Download

October 20, 2021

bioMérieux – Third-Quarter 2021 Business Review

Download

September 09, 2021

A survey in 5 European countries about sepsis demonstrates the lack of awareness and an expectation for faster diagnostic capabilities

Download

August 31, 2021

bioMérieux – First-Half 2021 Results

Download

June 29, 2021

In the fight against Antimicrobial Resistance, bioMérieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL® Rapid AST system in Europe

Download

June 28, 2021

bioMérieux launches EPISEQ® SARS-COV-2, a cloud-based software application for the epidemiological surveillance of SARS-CoV-2 variants

Download

May 07, 2021

bioMérieux announces the CE marking of the new generation semi-quantitative VIDAS® SARS-COV-2 IgG II serology test.

Download

April 27, 2021

bioMérieux announces CE-marking of the new MALDI-TOF mass spectrometry identification system: VITEK® MS PRIME

Download

April 26, 2021

bioMérieux – First-Quarter 2021 Business Review

Download

April 06, 2021

bioMérieux announces the CE marking of 3 dengue immunoassays on VIDAS®

Download

March 23, 2021

bioMérieux announces the CE marking of TB IGRA® test on VIDAS®

Download

March 17, 2021

BIOFIRE® Respiratory 2.1 (RP2.1) Panel with SARS-CoV-2 obtains De Novo FDA Authorization

Download

March 12, 2021

The Biotech Digital Campus joins forces with biotechnology schools and training organizations to develop the talents of tomorrow

Download

February 23, 2021

bioMérieux – 2020 Financial Results

Download

February 02, 2021

bioMérieux announces the CE marking of NEPHROCHECK® test on VIDAS®

Download

April 09, 2021

Notice of information related to preparatory documents for the Ordinary and Extraordinary Shareholders’ Meeting of May 20, 2021

Download

No regulated information available

2020

September 10, 2020

Interim Financial Report 2020

Download

September 02, 2020

Notice of Publication of the 2020 HY Financial Report

Download

September 01, 2020

First-Half 2020 Results

Download

July 08, 2020

Second-Quarter 2020 Business Performance Preannouncement

Download

February 27, 2020

bioMérieux – 2019 Financial Results

Download

December 03, 2020

declaration_capital_et_droits_de_vote_au_30_11_2020_0.pdf

Download

November 04, 2020

declaration_capital_et_droits_de_vote_au_31_10_2020_0.pdf

Download

October 05, 2020

declaration_capital_et_droits_de_vote_au_30_09_2020_0.pdf

Download

September 03, 2020

declaration_capital_et_droits_de_vote_au_31_08_2020.pdf

Download

August 06, 2020

declaration_capital_et_droits_de_vote_au_31_07_2020.pdf

Download

July 08, 2020

declaration_capital_et_droits_de_vote_au_30_06_2020.pdf

Download

June 04, 2020

declaration_capital_et_droits_de_vote_au_31_05_2020.pdf

Download

May 07, 2020

declaration_capital_et_droits_de_vote_au_30_04_2020_0.pdf

Download

April 06, 2020

declaration_capital_et_droits_de_vote_au_31_03_2020.pdf

Download

March 05, 2020

declaration_capital_et_droits_de_vote_au_29_02_2020.pdf

Download

February 12, 2020

declaration_capital_et_droits_de_vote_au_30_01_2020.pdf

Download

January 13, 2020

declaration_capital_et_droits_de_vote_au_31_12_2019.pdf

Download

No regulated information available

December 03, 2020

November 2020 - Declaration about number of shares issued and number of voting rights

Download

November 04, 2020

October 2020 - Declaration about number of shares issued and number of voting rights

Download

October 05, 2020

September 2020 - Declaration about number of shares issued and number of voting rights

Download

September 03, 2020

August 2020 - Declaration about number of shares issued and number of voting rights

Download

August 06, 2020

July 2020 - Declaration about number of shares issued and number of voting rights

Download

July 08, 2020

June 2020 - Declaration about number of shares issued and number of voting rights

Download

June 04, 2020

May 2020 - Declaration about number of shares issued and number of voting rights

Download

May 07, 2020

April 2020 - Declaration about number of shares issued and number of voting rights

Download

April 06, 2020

March 2020 - Declaration about number of shares issued and number of voting rights

Download

March 05, 2020

February 2020 - Declaration about number of shares issued and number of voting rights

Download

February 12, 2020

January 2020 - Declaration about number of shares issued and number of voting rights

Download

January 13, 2020

December 2019 - Declaration about number of shares issued and number of voting rights

Download

No regulated information available

December 15, 2020

bioMérieux announces the CE marking of its molecular biology ARGENE® test for the simultaneous detection of SARS-CoV-2, influenza viruses A and B, and RSV and hMPV viruses

Download

December 14, 2020

Increased outlook for full-year 2020

Download

December 14, 2020

The French bioproduction sector announces the creation of Campus Biotech Digital, a platform unique in the world for bioproduction training

Download

December 02, 2020

BIOASTER, Université de Technologie de Compiègne, Hospices Civils de Lyon and bioMérieux formalize strategic collaboration to conduct Next Generation Sequencing technology evaluation in microbiology

Download

November 16, 2020

bioMérieux announces the expansion of the CE marking of its molecular biology ARGENE® SARS-CoV-2 diagnostic test to include saliva specimens.

Download

October 21, 2020

bioMérieux – Third-Quarter 2020 Business Review

Download

October 09, 2020

AMSP partners with bioMérieux to facilitate supply of high-quality COVID-19 diagnostics

Download

July 15, 2020

Launch of BIOFIRE® MYCOPLASMA test for mycoplasma detection in biopharmaceutical products

Download

July 14, 2020

BIOFIRE® Respiratory Panel 2.1 plus with SARS-CoV-2 is CE marked

Download

June 29, 2020

bioMérieux issues a €200 million Euro PP bond

Download

May 20, 2020

CE marking of bioMérieux serology tests for SARS-CoV-2 on VIDAS®

Download

May 19, 2020

Information concerning 2019 dividend and the bioMérieux General Shareholders’ Meeting

Download

May 05, 2020

bioMérieux serology tests for SARS-CoV-2 on VIDAS® undergo validation preceding imminent launch

Download

May 03, 2020

BIOFIRE® Respiratory Panel 2.1 (RP2.1) with SARS-CoV-2 obtains FDA Emergency Use Authorization

Download

April 15, 2020

First-Quarter 2020 Business Review

Download

March 23, 2020

bioMérieux receives Emergency Use Authorization for BIOFIRE COVID-19 test

Download

March 10, 2020

First of 3 diagnostic tests for SARS-CoV-2 coronavirus available from bioMérieux

Download

January 13, 2020

bioMérieux submits enhanced BIOFIRE BCID2 Panel for FDA clearance

Download

May 22, 2020

Notice of information related to preparatory documents for the Ordinary and Extraordinary Shareholders’ Meeting of June 30, 2020

Download

No regulated information available

2019

October 21, 2019

bioMérieux –Third-Quarter 2019 Business Review

Download

September 11, 2019

Interim financial report 2018

Download

September 05, 2019

Avis de mise à disposition du rapport financier semestriel 2019

Download

September 03, 2019

bioMérieux – First-Half 2019 Results

Download

April 23, 2019

bioMérieux – First-Quarter 2019 Business Review

Download

No regulated information available

December 06, 2019

November 2019 - Declaration about number of shares issued and number of voting rights

Download

November 08, 2019

October 2019 - Declaration about number of shares issued and number of voting rights

Download

October 07, 2019

September 2019 - Declaration about number of shares issued and number of voting rights

Download

September 05, 2019

August 2019 - Declaration about number of shares issued and number of voting rights

Download

August 07, 2019

July 2019 - Declaration about number of shares issued and number of voting rights

Download

July 04, 2019

June 2019 - Declaration about number of shares issued and number of voting rights

Download

June 11, 2019

May 2019 - Declaration about number of shares issued and number of voting rights

Download

May 06, 2019

April 2019 - Declaration about number of shares issued and number of voting rights

Download

April 05, 2019

March 2019 - Declaration about number of shares issued and number of voting

Download

March 06, 2019

February 2019 - Declaration about number of shares issued and number of voting rights

Download

February 07, 2019

January 2019 - Declaration about number of shares issued and number of voting rights

Download

January 07, 2019

December 2018 - Declaration about number of shares issued and number of voting rights

Download

No regulated information available

December 17, 2019

bioMérieux and the Fleming Fund: working together to strengthen diagnostic capacity and tackle antimicrobial resistance in low- and middle-income countries

Download

October 21, 2019

Third-Quarter 2019 Business Review

Download

September 04, 2019

First-Half 2019 Results - September 4, 2019

Download

June 05, 2019

bioMérieux increases its holding in Hybiome from 54% to 67%

Download

May 12, 2019

NEPHROCHECK Biomarkers TIMP-2 and IGFBP7 Included in the ERAS "Guidelines for Perioperative Care in Cardiac Surgery”

Download

April 23, 2019

bioMérieux – First-Quarter 2019 Business Review

Download

April 15, 2019

(bioMérieux Communiqué de mise à disposition du document de référence incluant le rapport financier annuel 2016)

Download

April 14, 2019

“Global-PPS”, a survey of antibiotic use and bacterial resistance in hospitals worldwide, tops the 200,000 patients

Download

March 29, 2019

University of Antwerp, bioMérieux, and Wellcome Trust to coordinate VALUE-Dx, a European Public-Private Partnership to fight antimicrobial resistance through diagnostics

Download

March 18, 2019

Baxter and bioMérieux announce collaboration to improve identification and treatment of acute kidney injury

Download

February 27, 2019

bioMérieux – 2018 Financial Results

Download

February 06, 2019

bioMérieux acquires Invisible Sentinel, a US-based company specialized in food and beverage molecular testing

Download

January 11, 2019

Follow up of the market making agreement at Dec 31, 2018

Download

No regulated information available

2018

October 23, 2018

bioMérieux – Business review for the nine months ended September 30, 2018

Download

September 14, 2018

Interim financial report 2018

Download

September 05, 2018

Avis_mise_a_disposition_rapport_financier_semestriel_2018

Download

September 04, 2018

bioMérieux – First-Half 2018 Results

Download

April 18, 2018

bioMérieux – First-Quarter 2018 Business Review

Download

Regulated Information

Search by Year

2024

Prospectus referring to Public offering

Fees received by Statutory auditors

Annual, biannual and quaterly information

Total number of voting rights and shares

Press Releases

General meeting preparatory documents

Information published pursuant to article 223-21 of the AMF regulation

Shares repurchase

Financial security, Law report of the Chairman of the Board on Corporate governance and internal contral

2023

Annual, biannual and quaterly information

Financial security, Law report of the chairman of the Board on Corporate governance and internal control report

Fees received by Statutory auditors

Total number of voting rights and shares

Prospectus referring to Public offering

Press Releases

General meeting preparatory documents

Shares repurchase

Information published pursuant to article 223-21 of the AMF regulation

2022

Annual, biannual and quaterly information

Financial security, Law report of the chairman of the Board on Corporate governance and internal control report

Fees received by Statutory auditors

Total number of voting rights and shares